ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Targeted Drugs for Breast Cancer Market Research Report 2025
Published Date: September 2025
|
Report Code: QYRE-Auto-17F6058
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Targeted Drugs for Breast Cancer Market Insights and Forecast to 2028
BUY CHAPTERS

Global Targeted Drugs for Breast Cancer Market Research Report 2025

Code: QYRE-Auto-17F6058
Report
September 2025
Pages:101
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Roche
TEVA
Mylan NV
Hikma
Hengrui Medicine
Cipla Ltd
Reliance Group
Hetero
Pfizer Inc
Eli Lilly
Novartis
CANbridge
Puma Biotechnology
Astrazeneca plc
Chugai Pharmaceutical
Eisai Co Ltd
GlaxoSmithKline PLC
Bristol–Myers Squibb
Otsuka Pharmaceutical
Merck
BioMarin
Hengrui Pharmaceutical
Beijing Biostar Technologies
Bayer

Targeted Drugs for Breast Cancer Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

Targeted Drugs for Breast Cancer Market

Targeted Drugs for Breast Cancer Market

The global market for Targeted Drugs for Breast Cancer was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Targeted Drugs for Breast Cancer, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Targeted Drugs for Breast Cancer.
The Targeted Drugs for Breast Cancer market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Targeted Drugs for Breast Cancer market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Targeted Drugs for Breast Cancer companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of Targeted Drugs for Breast Cancer Market Report

Report Metric Details
Report Name Targeted Drugs for Breast Cancer Market
CAGR 5%
Segment by Type
  • HER-2 Targeted Drugs
  • CDK4/6 Inhibitors
  • PARP Targeted Drugs
  • PI3K/AKT/mTor Pathway Inhibitors
  • ER Targeted Drugs
  • Aromatase Inhibitors
  • Tubulin Inhibitors
  • VEGF Targeted Drugs
  • YTMS Targeted Drugs
  • Others
Segment by Application
  • Hospital
  • Clinic
  • Drug Center
  • Others
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Roche, Teva, Mylan, Hikma, Hengrui Medicine, Cipla, Reliance Group, Hetero, Pfizer, Eli Lilly, Novartis, CANbridge, Puma Biotechnology, AstraZeneca, Chugai Pharmaceutical, Eisai, GlaxoSmithKline, Bristol-Myers Squibb, Otsuka Pharmaceutical, Merck, BioMarin, Hengrui Pharmaceutical, Beijing Biostar Technologies, Bayer
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of Targeted Drugs for Breast Cancer company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
  • Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Targeted Drugs for Breast Cancer Market report?

Ans: The main players in the Targeted Drugs for Breast Cancer Market are Roche, Teva, Mylan, Hikma, Hengrui Medicine, Cipla, Reliance Group, Hetero, Pfizer, Eli Lilly, Novartis, CANbridge, Puma Biotechnology, AstraZeneca, Chugai Pharmaceutical, Eisai, GlaxoSmithKline, Bristol-Myers Squibb, Otsuka Pharmaceutical, Merck, BioMarin, Hengrui Pharmaceutical, Beijing Biostar Technologies, Bayer

What are the Application segmentation covered in the Targeted Drugs for Breast Cancer Market report?

Ans: The Applications covered in the Targeted Drugs for Breast Cancer Market report are Hospital, Clinic, Drug Center, Others

What are the Type segmentation covered in the Targeted Drugs for Breast Cancer Market report?

Ans: The Types covered in the Targeted Drugs for Breast Cancer Market report are HER-2 Targeted Drugs, CDK4/6 Inhibitors, PARP Targeted Drugs, PI3K/AKT/mTor Pathway Inhibitors, ER Targeted Drugs, Aromatase Inhibitors, Tubulin Inhibitors, VEGF Targeted Drugs, YTMS Targeted Drugs, Others

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Targeted Drugs for Breast Cancer Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 HER-2 Targeted Drugs
1.2.3 CDK4/6 Inhibitors
1.2.4 PARP Targeted Drugs
1.2.5 PI3K/AKT/mTor Pathway Inhibitors
1.2.6 ER Targeted Drugs
1.2.7 Aromatase Inhibitors
1.2.8 Tubulin Inhibitors
1.2.9 VEGF Targeted Drugs
1.2.10 YTMS Targeted Drugs
1.3 Market by Application
1.3.1 Global Targeted Drugs for Breast Cancer Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Drug Center
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Targeted Drugs for Breast Cancer Market Perspective (2020-2031)
2.2 Global Targeted Drugs for Breast Cancer Growth Trends by Region
2.2.1 Global Targeted Drugs for Breast Cancer Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Targeted Drugs for Breast Cancer Historic Market Size by Region (2020-2025)
2.2.3 Targeted Drugs for Breast Cancer Forecasted Market Size by Region (2026-2031)
2.3 Targeted Drugs for Breast Cancer Market Dynamics
2.3.1 Targeted Drugs for Breast Cancer Industry Trends
2.3.2 Targeted Drugs for Breast Cancer Market Drivers
2.3.3 Targeted Drugs for Breast Cancer Market Challenges
2.3.4 Targeted Drugs for Breast Cancer Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Targeted Drugs for Breast Cancer Players by Revenue
3.1.1 Global Top Targeted Drugs for Breast Cancer Players by Revenue (2020-2025)
3.1.2 Global Targeted Drugs for Breast Cancer Revenue Market Share by Players (2020-2025)
3.2 Global Targeted Drugs for Breast Cancer Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Targeted Drugs for Breast Cancer Revenue
3.4 Global Targeted Drugs for Breast Cancer Market Concentration Ratio
3.4.1 Global Targeted Drugs for Breast Cancer Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Targeted Drugs for Breast Cancer Revenue in 2024
3.5 Global Key Players of Targeted Drugs for Breast Cancer Head office and Area Served
3.6 Global Key Players of Targeted Drugs for Breast Cancer, Product and Application
3.7 Global Key Players of Targeted Drugs for Breast Cancer, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Targeted Drugs for Breast Cancer Breakdown Data by Type
4.1 Global Targeted Drugs for Breast Cancer Historic Market Size by Type (2020-2025)
4.2 Global Targeted Drugs for Breast Cancer Forecasted Market Size by Type (2026-2031)
5 Targeted Drugs for Breast Cancer Breakdown Data by Application
5.1 Global Targeted Drugs for Breast Cancer Historic Market Size by Application (2020-2025)
5.2 Global Targeted Drugs for Breast Cancer Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Targeted Drugs for Breast Cancer Market Size (2020-2031)
6.2 North America Targeted Drugs for Breast Cancer Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Targeted Drugs for Breast Cancer Market Size by Country (2020-2025)
6.4 North America Targeted Drugs for Breast Cancer Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Targeted Drugs for Breast Cancer Market Size (2020-2031)
7.2 Europe Targeted Drugs for Breast Cancer Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Targeted Drugs for Breast Cancer Market Size by Country (2020-2025)
7.4 Europe Targeted Drugs for Breast Cancer Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Targeted Drugs for Breast Cancer Market Size (2020-2031)
8.2 Asia-Pacific Targeted Drugs for Breast Cancer Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Targeted Drugs for Breast Cancer Market Size by Region (2020-2025)
8.4 Asia-Pacific Targeted Drugs for Breast Cancer Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Targeted Drugs for Breast Cancer Market Size (2020-2031)
9.2 Latin America Targeted Drugs for Breast Cancer Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Targeted Drugs for Breast Cancer Market Size by Country (2020-2025)
9.4 Latin America Targeted Drugs for Breast Cancer Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Targeted Drugs for Breast Cancer Market Size (2020-2031)
10.2 Middle East & Africa Targeted Drugs for Breast Cancer Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Targeted Drugs for Breast Cancer Market Size by Country (2020-2025)
10.4 Middle East & Africa Targeted Drugs for Breast Cancer Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Roche
11.1.1 Roche Company Details
11.1.2 Roche Business Overview
11.1.3 Roche Targeted Drugs for Breast Cancer Introduction
11.1.4 Roche Revenue in Targeted Drugs for Breast Cancer Business (2020-2025)
11.1.5 Roche Recent Development
11.2 Teva
11.2.1 Teva Company Details
11.2.2 Teva Business Overview
11.2.3 Teva Targeted Drugs for Breast Cancer Introduction
11.2.4 Teva Revenue in Targeted Drugs for Breast Cancer Business (2020-2025)
11.2.5 Teva Recent Development
11.3 Mylan
11.3.1 Mylan Company Details
11.3.2 Mylan Business Overview
11.3.3 Mylan Targeted Drugs for Breast Cancer Introduction
11.3.4 Mylan Revenue in Targeted Drugs for Breast Cancer Business (2020-2025)
11.3.5 Mylan Recent Development
11.4 Hikma
11.4.1 Hikma Company Details
11.4.2 Hikma Business Overview
11.4.3 Hikma Targeted Drugs for Breast Cancer Introduction
11.4.4 Hikma Revenue in Targeted Drugs for Breast Cancer Business (2020-2025)
11.4.5 Hikma Recent Development
11.5 Hengrui Medicine
11.5.1 Hengrui Medicine Company Details
11.5.2 Hengrui Medicine Business Overview
11.5.3 Hengrui Medicine Targeted Drugs for Breast Cancer Introduction
11.5.4 Hengrui Medicine Revenue in Targeted Drugs for Breast Cancer Business (2020-2025)
11.5.5 Hengrui Medicine Recent Development
11.6 Cipla
11.6.1 Cipla Company Details
11.6.2 Cipla Business Overview
11.6.3 Cipla Targeted Drugs for Breast Cancer Introduction
11.6.4 Cipla Revenue in Targeted Drugs for Breast Cancer Business (2020-2025)
11.6.5 Cipla Recent Development
11.7 Reliance Group
11.7.1 Reliance Group Company Details
11.7.2 Reliance Group Business Overview
11.7.3 Reliance Group Targeted Drugs for Breast Cancer Introduction
11.7.4 Reliance Group Revenue in Targeted Drugs for Breast Cancer Business (2020-2025)
11.7.5 Reliance Group Recent Development
11.8 Hetero
11.8.1 Hetero Company Details
11.8.2 Hetero Business Overview
11.8.3 Hetero Targeted Drugs for Breast Cancer Introduction
11.8.4 Hetero Revenue in Targeted Drugs for Breast Cancer Business (2020-2025)
11.8.5 Hetero Recent Development
11.9 Pfizer
11.9.1 Pfizer Company Details
11.9.2 Pfizer Business Overview
11.9.3 Pfizer Targeted Drugs for Breast Cancer Introduction
11.9.4 Pfizer Revenue in Targeted Drugs for Breast Cancer Business (2020-2025)
11.9.5 Pfizer Recent Development
11.10 Eli Lilly
11.10.1 Eli Lilly Company Details
11.10.2 Eli Lilly Business Overview
11.10.3 Eli Lilly Targeted Drugs for Breast Cancer Introduction
11.10.4 Eli Lilly Revenue in Targeted Drugs for Breast Cancer Business (2020-2025)
11.10.5 Eli Lilly Recent Development
11.11 Novartis
11.11.1 Novartis Company Details
11.11.2 Novartis Business Overview
11.11.3 Novartis Targeted Drugs for Breast Cancer Introduction
11.11.4 Novartis Revenue in Targeted Drugs for Breast Cancer Business (2020-2025)
11.11.5 Novartis Recent Development
11.12 CANbridge
11.12.1 CANbridge Company Details
11.12.2 CANbridge Business Overview
11.12.3 CANbridge Targeted Drugs for Breast Cancer Introduction
11.12.4 CANbridge Revenue in Targeted Drugs for Breast Cancer Business (2020-2025)
11.12.5 CANbridge Recent Development
11.13 Puma Biotechnology
11.13.1 Puma Biotechnology Company Details
11.13.2 Puma Biotechnology Business Overview
11.13.3 Puma Biotechnology Targeted Drugs for Breast Cancer Introduction
11.13.4 Puma Biotechnology Revenue in Targeted Drugs for Breast Cancer Business (2020-2025)
11.13.5 Puma Biotechnology Recent Development
11.14 AstraZeneca
11.14.1 AstraZeneca Company Details
11.14.2 AstraZeneca Business Overview
11.14.3 AstraZeneca Targeted Drugs for Breast Cancer Introduction
11.14.4 AstraZeneca Revenue in Targeted Drugs for Breast Cancer Business (2020-2025)
11.14.5 AstraZeneca Recent Development
11.15 Chugai Pharmaceutical
11.15.1 Chugai Pharmaceutical Company Details
11.15.2 Chugai Pharmaceutical Business Overview
11.15.3 Chugai Pharmaceutical Targeted Drugs for Breast Cancer Introduction
11.15.4 Chugai Pharmaceutical Revenue in Targeted Drugs for Breast Cancer Business (2020-2025)
11.15.5 Chugai Pharmaceutical Recent Development
11.16 Eisai
11.16.1 Eisai Company Details
11.16.2 Eisai Business Overview
11.16.3 Eisai Targeted Drugs for Breast Cancer Introduction
11.16.4 Eisai Revenue in Targeted Drugs for Breast Cancer Business (2020-2025)
11.16.5 Eisai Recent Development
11.17 GlaxoSmithKline
11.17.1 GlaxoSmithKline Company Details
11.17.2 GlaxoSmithKline Business Overview
11.17.3 GlaxoSmithKline Targeted Drugs for Breast Cancer Introduction
11.17.4 GlaxoSmithKline Revenue in Targeted Drugs for Breast Cancer Business (2020-2025)
11.17.5 GlaxoSmithKline Recent Development
11.18 Bristol-Myers Squibb
11.18.1 Bristol-Myers Squibb Company Details
11.18.2 Bristol-Myers Squibb Business Overview
11.18.3 Bristol-Myers Squibb Targeted Drugs for Breast Cancer Introduction
11.18.4 Bristol-Myers Squibb Revenue in Targeted Drugs for Breast Cancer Business (2020-2025)
11.18.5 Bristol-Myers Squibb Recent Development
11.19 Otsuka Pharmaceutical
11.19.1 Otsuka Pharmaceutical Company Details
11.19.2 Otsuka Pharmaceutical Business Overview
11.19.3 Otsuka Pharmaceutical Targeted Drugs for Breast Cancer Introduction
11.19.4 Otsuka Pharmaceutical Revenue in Targeted Drugs for Breast Cancer Business (2020-2025)
11.19.5 Otsuka Pharmaceutical Recent Development
11.20 Merck
11.20.1 Merck Company Details
11.20.2 Merck Business Overview
11.20.3 Merck Targeted Drugs for Breast Cancer Introduction
11.20.4 Merck Revenue in Targeted Drugs for Breast Cancer Business (2020-2025)
11.20.5 Merck Recent Development
11.21 BioMarin
11.21.1 BioMarin Company Details
11.21.2 BioMarin Business Overview
11.21.3 BioMarin Targeted Drugs for Breast Cancer Introduction
11.21.4 BioMarin Revenue in Targeted Drugs for Breast Cancer Business (2020-2025)
11.21.5 BioMarin Recent Development
11.22 Hengrui Pharmaceutical
11.22.1 Hengrui Pharmaceutical Company Details
11.22.2 Hengrui Pharmaceutical Business Overview
11.22.3 Hengrui Pharmaceutical Targeted Drugs for Breast Cancer Introduction
11.22.4 Hengrui Pharmaceutical Revenue in Targeted Drugs for Breast Cancer Business (2020-2025)
11.22.5 Hengrui Pharmaceutical Recent Development
11.23 Beijing Biostar Technologies
11.23.1 Beijing Biostar Technologies Company Details
11.23.2 Beijing Biostar Technologies Business Overview
11.23.3 Beijing Biostar Technologies Targeted Drugs for Breast Cancer Introduction
11.23.4 Beijing Biostar Technologies Revenue in Targeted Drugs for Breast Cancer Business (2020-2025)
11.23.5 Beijing Biostar Technologies Recent Development
11.24 Bayer
11.24.1 Bayer Company Details
11.24.2 Bayer Business Overview
11.24.3 Bayer Targeted Drugs for Breast Cancer Introduction
11.24.4 Bayer Revenue in Targeted Drugs for Breast Cancer Business (2020-2025)
11.24.5 Bayer Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
FEATURED COMPANIES
Roche
TEVA
Mylan NV
Hikma
Hengrui Medicine
Cipla Ltd
Reliance Group
Hetero
Pfizer Inc
Eli Lilly
Novartis
CANbridge
Puma Biotechnology
Astrazeneca plc
Chugai Pharmaceutical
Eisai Co Ltd
GlaxoSmithKline PLC
Bristol–Myers Squibb
Otsuka Pharmaceutical
Merck
BioMarin
Hengrui Pharmaceutical
Beijing Biostar Technologies
Bayer
List of Tables
 Table 1. Global Targeted Drugs for Breast Cancer Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
 Table 2. Key Players of HER-2 Targeted Drugs
 Table 3. Key Players of CDK4/6 Inhibitors
 Table 4. Key Players of PARP Targeted Drugs
 Table 5. Key Players of PI3K/AKT/mTor Pathway Inhibitors
 Table 6. Key Players of ER Targeted Drugs
 Table 7. Key Players of Aromatase Inhibitors
 Table 8. Key Players of Tubulin Inhibitors
 Table 9. Global Targeted Drugs for Breast Cancer Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
 Table 10. Global Targeted Drugs for Breast Cancer Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 11. Global Targeted Drugs for Breast Cancer Market Size by Region (2020-2025) & (US$ Million)
 Table 12. Global Targeted Drugs for Breast Cancer Market Share by Region (2020-2025)
 Table 13. Global Targeted Drugs for Breast Cancer Forecasted Market Size by Region (2026-2031) & (US$ Million)
 Table 14. Global Targeted Drugs for Breast Cancer Market Share by Region (2026-2031)
 Table 15. Targeted Drugs for Breast Cancer Market Trends
 Table 16. Targeted Drugs for Breast Cancer Market Drivers
 Table 17. Targeted Drugs for Breast Cancer Market Challenges
 Table 18. Targeted Drugs for Breast Cancer Market Restraints
 Table 19. Global Targeted Drugs for Breast Cancer Revenue by Players (2020-2025) & (US$ Million)
 Table 20. Global Targeted Drugs for Breast Cancer Market Share by Players (2020-2025)
 Table 21. Global Top Targeted Drugs for Breast Cancer Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Targeted Drugs for Breast Cancer as of 2024)
 Table 22. Ranking of Global Top Targeted Drugs for Breast Cancer Companies by Revenue (US$ Million) in 2024
 Table 23. Global 5 Largest Players Market Share by Targeted Drugs for Breast Cancer Revenue (CR5 and HHI) & (2020-2025)
 Table 24. Global Key Players of Targeted Drugs for Breast Cancer, Headquarters and Area Served
 Table 25. Global Key Players of Targeted Drugs for Breast Cancer, Product and Application
 Table 26. Global Key Players of Targeted Drugs for Breast Cancer, Date of Enter into This Industry
 Table 27. Mergers & Acquisitions, Expansion Plans
 Table 28. Global Targeted Drugs for Breast Cancer Market Size by Type (2020-2025) & (US$ Million)
 Table 29. Global Targeted Drugs for Breast Cancer Revenue Market Share by Type (2020-2025)
 Table 30. Global Targeted Drugs for Breast Cancer Forecasted Market Size by Type (2026-2031) & (US$ Million)
 Table 31. Global Targeted Drugs for Breast Cancer Revenue Market Share by Type (2026-2031)
 Table 32. Global Targeted Drugs for Breast Cancer Market Size by Application (2020-2025) & (US$ Million)
 Table 33. Global Targeted Drugs for Breast Cancer Revenue Market Share by Application (2020-2025)
 Table 34. Global Targeted Drugs for Breast Cancer Forecasted Market Size by Application (2026-2031) & (US$ Million)
 Table 35. Global Targeted Drugs for Breast Cancer Revenue Market Share by Application (2026-2031)
 Table 36. North America Targeted Drugs for Breast Cancer Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 37. North America Targeted Drugs for Breast Cancer Market Size by Country (2020-2025) & (US$ Million)
 Table 38. North America Targeted Drugs for Breast Cancer Market Size by Country (2026-2031) & (US$ Million)
 Table 39. Europe Targeted Drugs for Breast Cancer Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 40. Europe Targeted Drugs for Breast Cancer Market Size by Country (2020-2025) & (US$ Million)
 Table 41. Europe Targeted Drugs for Breast Cancer Market Size by Country (2026-2031) & (US$ Million)
 Table 42. Asia-Pacific Targeted Drugs for Breast Cancer Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 43. Asia-Pacific Targeted Drugs for Breast Cancer Market Size by Region (2020-2025) & (US$ Million)
 Table 44. Asia-Pacific Targeted Drugs for Breast Cancer Market Size by Region (2026-2031) & (US$ Million)
 Table 45. Latin America Targeted Drugs for Breast Cancer Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 46. Latin America Targeted Drugs for Breast Cancer Market Size by Country (2020-2025) & (US$ Million)
 Table 47. Latin America Targeted Drugs for Breast Cancer Market Size by Country (2026-2031) & (US$ Million)
 Table 48. Middle East & Africa Targeted Drugs for Breast Cancer Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 49. Middle East & Africa Targeted Drugs for Breast Cancer Market Size by Country (2020-2025) & (US$ Million)
 Table 50. Middle East & Africa Targeted Drugs for Breast Cancer Market Size by Country (2026-2031) & (US$ Million)
 Table 51. Roche Company Details
 Table 52. Roche Business Overview
 Table 53. Roche Targeted Drugs for Breast Cancer Product
 Table 54. Roche Revenue in Targeted Drugs for Breast Cancer Business (2020-2025) & (US$ Million)
 Table 55. Roche Recent Development
 Table 56. Teva Company Details
 Table 57. Teva Business Overview
 Table 58. Teva Targeted Drugs for Breast Cancer Product
 Table 59. Teva Revenue in Targeted Drugs for Breast Cancer Business (2020-2025) & (US$ Million)
 Table 60. Teva Recent Development
 Table 61. Mylan Company Details
 Table 62. Mylan Business Overview
 Table 63. Mylan Targeted Drugs for Breast Cancer Product
 Table 64. Mylan Revenue in Targeted Drugs for Breast Cancer Business (2020-2025) & (US$ Million)
 Table 65. Mylan Recent Development
 Table 66. Hikma Company Details
 Table 67. Hikma Business Overview
 Table 68. Hikma Targeted Drugs for Breast Cancer Product
 Table 69. Hikma Revenue in Targeted Drugs for Breast Cancer Business (2020-2025) & (US$ Million)
 Table 70. Hikma Recent Development
 Table 71. Hengrui Medicine Company Details
 Table 72. Hengrui Medicine Business Overview
 Table 73. Hengrui Medicine Targeted Drugs for Breast Cancer Product
 Table 74. Hengrui Medicine Revenue in Targeted Drugs for Breast Cancer Business (2020-2025) & (US$ Million)
 Table 75. Hengrui Medicine Recent Development
 Table 76. Cipla Company Details
 Table 77. Cipla Business Overview
 Table 78. Cipla Targeted Drugs for Breast Cancer Product
 Table 79. Cipla Revenue in Targeted Drugs for Breast Cancer Business (2020-2025) & (US$ Million)
 Table 80. Cipla Recent Development
 Table 81. Reliance Group Company Details
 Table 82. Reliance Group Business Overview
 Table 83. Reliance Group Targeted Drugs for Breast Cancer Product
 Table 84. Reliance Group Revenue in Targeted Drugs for Breast Cancer Business (2020-2025) & (US$ Million)
 Table 85. Reliance Group Recent Development
 Table 86. Hetero Company Details
 Table 87. Hetero Business Overview
 Table 88. Hetero Targeted Drugs for Breast Cancer Product
 Table 89. Hetero Revenue in Targeted Drugs for Breast Cancer Business (2020-2025) & (US$ Million)
 Table 90. Hetero Recent Development
 Table 91. Pfizer Company Details
 Table 92. Pfizer Business Overview
 Table 93. Pfizer Targeted Drugs for Breast Cancer Product
 Table 94. Pfizer Revenue in Targeted Drugs for Breast Cancer Business (2020-2025) & (US$ Million)
 Table 95. Pfizer Recent Development
 Table 96. Eli Lilly Company Details
 Table 97. Eli Lilly Business Overview
 Table 98. Eli Lilly Targeted Drugs for Breast Cancer Product
 Table 99. Eli Lilly Revenue in Targeted Drugs for Breast Cancer Business (2020-2025) & (US$ Million)
 Table 100. Eli Lilly Recent Development
 Table 101. Novartis Company Details
 Table 102. Novartis Business Overview
 Table 103. Novartis Targeted Drugs for Breast Cancer Product
 Table 104. Novartis Revenue in Targeted Drugs for Breast Cancer Business (2020-2025) & (US$ Million)
 Table 105. Novartis Recent Development
 Table 106. CANbridge Company Details
 Table 107. CANbridge Business Overview
 Table 108. CANbridge Targeted Drugs for Breast Cancer Product
 Table 109. CANbridge Revenue in Targeted Drugs for Breast Cancer Business (2020-2025) & (US$ Million)
 Table 110. CANbridge Recent Development
 Table 111. Puma Biotechnology Company Details
 Table 112. Puma Biotechnology Business Overview
 Table 113. Puma Biotechnology Targeted Drugs for Breast Cancer Product
 Table 114. Puma Biotechnology Revenue in Targeted Drugs for Breast Cancer Business (2020-2025) & (US$ Million)
 Table 115. Puma Biotechnology Recent Development
 Table 116. AstraZeneca Company Details
 Table 117. AstraZeneca Business Overview
 Table 118. AstraZeneca Targeted Drugs for Breast Cancer Product
 Table 119. AstraZeneca Revenue in Targeted Drugs for Breast Cancer Business (2020-2025) & (US$ Million)
 Table 120. AstraZeneca Recent Development
 Table 121. Chugai Pharmaceutical Company Details
 Table 122. Chugai Pharmaceutical Business Overview
 Table 123. Chugai Pharmaceutical Targeted Drugs for Breast Cancer Product
 Table 124. Chugai Pharmaceutical Revenue in Targeted Drugs for Breast Cancer Business (2020-2025) & (US$ Million)
 Table 125. Chugai Pharmaceutical Recent Development
 Table 126. Eisai Company Details
 Table 127. Eisai Business Overview
 Table 128. Eisai Targeted Drugs for Breast Cancer Product
 Table 129. Eisai Revenue in Targeted Drugs for Breast Cancer Business (2020-2025) & (US$ Million)
 Table 130. Eisai Recent Development
 Table 131. GlaxoSmithKline Company Details
 Table 132. GlaxoSmithKline Business Overview
 Table 133. GlaxoSmithKline Targeted Drugs for Breast Cancer Product
 Table 134. GlaxoSmithKline Revenue in Targeted Drugs for Breast Cancer Business (2020-2025) & (US$ Million)
 Table 135. GlaxoSmithKline Recent Development
 Table 136. Bristol-Myers Squibb Company Details
 Table 137. Bristol-Myers Squibb Business Overview
 Table 138. Bristol-Myers Squibb Targeted Drugs for Breast Cancer Product
 Table 139. Bristol-Myers Squibb Revenue in Targeted Drugs for Breast Cancer Business (2020-2025) & (US$ Million)
 Table 140. Bristol-Myers Squibb Recent Development
 Table 141. Otsuka Pharmaceutical Company Details
 Table 142. Otsuka Pharmaceutical Business Overview
 Table 143. Otsuka Pharmaceutical Targeted Drugs for Breast Cancer Product
 Table 144. Otsuka Pharmaceutical Revenue in Targeted Drugs for Breast Cancer Business (2020-2025) & (US$ Million)
 Table 145. Otsuka Pharmaceutical Recent Development
 Table 146. Merck Company Details
 Table 147. Merck Business Overview
 Table 148. Merck Targeted Drugs for Breast Cancer Product
 Table 149. Merck Revenue in Targeted Drugs for Breast Cancer Business (2020-2025) & (US$ Million)
 Table 150. Merck Recent Development
 Table 151. BioMarin Company Details
 Table 152. BioMarin Business Overview
 Table 153. BioMarin Targeted Drugs for Breast Cancer Product
 Table 154. BioMarin Revenue in Targeted Drugs for Breast Cancer Business (2020-2025) & (US$ Million)
 Table 155. BioMarin Recent Development
 Table 156. Hengrui Pharmaceutical Company Details
 Table 157. Hengrui Pharmaceutical Business Overview
 Table 158. Hengrui Pharmaceutical Targeted Drugs for Breast Cancer Product
 Table 159. Hengrui Pharmaceutical Revenue in Targeted Drugs for Breast Cancer Business (2020-2025) & (US$ Million)
 Table 160. Hengrui Pharmaceutical Recent Development
 Table 161. Beijing Biostar Technologies Company Details
 Table 162. Beijing Biostar Technologies Business Overview
 Table 163. Beijing Biostar Technologies Targeted Drugs for Breast Cancer Product
 Table 164. Beijing Biostar Technologies Revenue in Targeted Drugs for Breast Cancer Business (2020-2025) & (US$ Million)
 Table 165. Beijing Biostar Technologies Recent Development
 Table 166. Bayer Company Details
 Table 167. Bayer Business Overview
 Table 168. Bayer Targeted Drugs for Breast Cancer Product
 Table 169. Bayer Revenue in Targeted Drugs for Breast Cancer Business (2020-2025) & (US$ Million)
 Table 170. Bayer Recent Development
 Table 171. Research Programs/Design for This Report
 Table 172. Key Data Information from Secondary Sources
 Table 173. Key Data Information from Primary Sources
 Table 174. Authors List of This Report


List of Figures
 Figure 1. Targeted Drugs for Breast Cancer Picture
 Figure 2. Global Targeted Drugs for Breast Cancer Market Size Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Targeted Drugs for Breast Cancer Market Share by Type: 2024 VS 2031
 Figure 4. HER-2 Targeted Drugs Features
 Figure 5. CDK4/6 Inhibitors Features
 Figure 6. PARP Targeted Drugs Features
 Figure 7. PI3K/AKT/mTor Pathway Inhibitors Features
 Figure 8. ER Targeted Drugs Features
 Figure 9. Aromatase Inhibitors Features
 Figure 10. Tubulin Inhibitors Features
 Figure 11. VEGF Targeted Drugs Features
 Figure 12. YTMS Targeted Drugs Features
 Figure 13. Global Targeted Drugs for Breast Cancer Market Size by Application (2020-2031) & (US$ Million)
 Figure 14. Global Targeted Drugs for Breast Cancer Market Share by Application: 2024 VS 2031
 Figure 15. Hospital Case Studies
 Figure 16. Clinic Case Studies
 Figure 17. Drug Center Case Studies
 Figure 18. Others Case Studies
 Figure 19. Targeted Drugs for Breast Cancer Report Years Considered
 Figure 20. Global Targeted Drugs for Breast Cancer Market Size (US$ Million), Year-over-Year: 2020-2031
 Figure 21. Global Targeted Drugs for Breast Cancer Market Size, (US$ Million), 2020 VS 2024 VS 2031
 Figure 22. Global Targeted Drugs for Breast Cancer Market Share by Region: 2024 VS 2031
 Figure 23. Global Targeted Drugs for Breast Cancer Market Share by Players in 2024
 Figure 24. Global Top Targeted Drugs for Breast Cancer Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Targeted Drugs for Breast Cancer as of 2024)
 Figure 25. The Top 10 and 5 Players Market Share by Targeted Drugs for Breast Cancer Revenue in 2024
 Figure 26. North America Targeted Drugs for Breast Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 27. North America Targeted Drugs for Breast Cancer Market Share by Country (2020-2031)
 Figure 28. United States Targeted Drugs for Breast Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 29. Canada Targeted Drugs for Breast Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 30. Europe Targeted Drugs for Breast Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 31. Europe Targeted Drugs for Breast Cancer Market Share by Country (2020-2031)
 Figure 32. Germany Targeted Drugs for Breast Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 33. France Targeted Drugs for Breast Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 34. U.K. Targeted Drugs for Breast Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 35. Italy Targeted Drugs for Breast Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 36. Russia Targeted Drugs for Breast Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 37. Nordic Countries Targeted Drugs for Breast Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 38. Asia-Pacific Targeted Drugs for Breast Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 39. Asia-Pacific Targeted Drugs for Breast Cancer Market Share by Region (2020-2031)
 Figure 40. China Targeted Drugs for Breast Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 41. Japan Targeted Drugs for Breast Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 42. South Korea Targeted Drugs for Breast Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 43. Southeast Asia Targeted Drugs for Breast Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 44. India Targeted Drugs for Breast Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 45. Australia Targeted Drugs for Breast Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 46. Latin America Targeted Drugs for Breast Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 47. Latin America Targeted Drugs for Breast Cancer Market Share by Country (2020-2031)
 Figure 48. Mexico Targeted Drugs for Breast Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 49. Brazil Targeted Drugs for Breast Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 50. Middle East & Africa Targeted Drugs for Breast Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 51. Middle East & Africa Targeted Drugs for Breast Cancer Market Share by Country (2020-2031)
 Figure 52. Turkey Targeted Drugs for Breast Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 53. Saudi Arabia Targeted Drugs for Breast Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 54. UAE Targeted Drugs for Breast Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 55. Roche Revenue Growth Rate in Targeted Drugs for Breast Cancer Business (2020-2025)
 Figure 56. Teva Revenue Growth Rate in Targeted Drugs for Breast Cancer Business (2020-2025)
 Figure 57. Mylan Revenue Growth Rate in Targeted Drugs for Breast Cancer Business (2020-2025)
 Figure 58. Hikma Revenue Growth Rate in Targeted Drugs for Breast Cancer Business (2020-2025)
 Figure 59. Hengrui Medicine Revenue Growth Rate in Targeted Drugs for Breast Cancer Business (2020-2025)
 Figure 60. Cipla Revenue Growth Rate in Targeted Drugs for Breast Cancer Business (2020-2025)
 Figure 61. Reliance Group Revenue Growth Rate in Targeted Drugs for Breast Cancer Business (2020-2025)
 Figure 62. Hetero Revenue Growth Rate in Targeted Drugs for Breast Cancer Business (2020-2025)
 Figure 63. Pfizer Revenue Growth Rate in Targeted Drugs for Breast Cancer Business (2020-2025)
 Figure 64. Eli Lilly Revenue Growth Rate in Targeted Drugs for Breast Cancer Business (2020-2025)
 Figure 65. Novartis Revenue Growth Rate in Targeted Drugs for Breast Cancer Business (2020-2025)
 Figure 66. CANbridge Revenue Growth Rate in Targeted Drugs for Breast Cancer Business (2020-2025)
 Figure 67. Puma Biotechnology Revenue Growth Rate in Targeted Drugs for Breast Cancer Business (2020-2025)
 Figure 68. AstraZeneca Revenue Growth Rate in Targeted Drugs for Breast Cancer Business (2020-2025)
 Figure 69. Chugai Pharmaceutical Revenue Growth Rate in Targeted Drugs for Breast Cancer Business (2020-2025)
 Figure 70. Eisai Revenue Growth Rate in Targeted Drugs for Breast Cancer Business (2020-2025)
 Figure 71. GlaxoSmithKline Revenue Growth Rate in Targeted Drugs for Breast Cancer Business (2020-2025)
 Figure 72. Bristol-Myers Squibb Revenue Growth Rate in Targeted Drugs for Breast Cancer Business (2020-2025)
 Figure 73. Otsuka Pharmaceutical Revenue Growth Rate in Targeted Drugs for Breast Cancer Business (2020-2025)
 Figure 74. Merck Revenue Growth Rate in Targeted Drugs for Breast Cancer Business (2020-2025)
 Figure 75. BioMarin Revenue Growth Rate in Targeted Drugs for Breast Cancer Business (2020-2025)
 Figure 76. Hengrui Pharmaceutical Revenue Growth Rate in Targeted Drugs for Breast Cancer Business (2020-2025)
 Figure 77. Beijing Biostar Technologies Revenue Growth Rate in Targeted Drugs for Breast Cancer Business (2020-2025)
 Figure 78. Bayer Revenue Growth Rate in Targeted Drugs for Breast Cancer Business (2020-2025)
 Figure 79. Bottom-up and Top-down Approaches for This Report
 Figure 80. Data Triangulation
 Figure 81. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Bioinformatics Barcelona

SIMILAR REPORTS

Global ER Targeted Drugs for Breast Cancer Market Research Report 2024
Global VEGF Targeted Drugs for Breast Cancer Market Research Report 2024
Global HER 2 Targeted Drugs for Breast Cancer Market Research Report 2024
Breast Cancer Therapy Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Endocrine Therapy Drugs for Breast Cancer Market Research Report 2024
Global Targeted Drugs for NSCLC Market Research Report 2024
Breast Cancer Generic Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Gynecological Cancers Drug Market Research Report 2025
Global Personalized Medicine for Cancer Market Research Report 2025
Oncology Anti cancer Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Cancer Therapeutics and Biotherapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Targeted Drug HER2 Inhibitors for NSCLC Market Research Report 2024
Global Prostate Cancer Diagnostics and Therapy Market Research Report 2024
Global Small Molecule Cancer Drug Market Research Report 2025
Novel Drug Delivery Systems for Cancer Therapy Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Cancers Immunotherapy Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Personalizing Cancer Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
AI for Cancer Diagnosis Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Kidney Cancer Diagnosis Market Research Report 2025
Precision Cancer Therapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions